Get Harrow alerts:Harrow, Inc. (NASDAQ:HROW – Free Report) – Research analysts at William Blair raised their Q1 2026 earnings estimates for shares of Harrow in a research note issued on Monday, September 29th. HC Wainwright reiterated a “buy” rating and issued a $64.00 target price on shares of Harrow in a research report on Monday. Cantor Fitzgerald initiated coverage on shares of Harrow in a research report on Friday, July 11th. Zacks Research cut shares of Harrow from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 12th. Harrow Company Profile(Get Free Report)Harrow, Inc operates as an ophthalmic-focused healthcare company.